James Love's blog

FOIA regarding General Electric's lobbying of USTR to oppose WIPO Treaty for the Blind.

We just received a reply from a September 17, 2013 FOIA request KEI filed with USTR, asking for correspondence involving General Electric's efforts to block the WIPO Treaty for the Blind. USTR provided 24 pages of documents, available here:


Harvey Bale, former Director General of IFPMA, says Fast Track "favors the powerful over the weak"

Following the Friday vote in the House of Representatives which effectively blocked movement (for now) on the Trade Promotion Authority, and more generally, slowed down the TransPacific Partnership (TPP) negotiations, I was contacted by Dr. Harvey Bale, the well known former Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). In an exchange on Facebook, Dr. Bale took favorable note of the outcome on fast track, and described the vote against fast track as "A very good day, Indeed." I asked Dr.

Article in Medium, on the TPP

I have written an article for Medium, titled: TPP, designed to make medicine more expensive, reforms more difficult. (Link here)

New leaks from RECP negotiations on IP, India and ASEAN proposals

Last week, KEI published the October 3, 2014 Korea proposals for the RCEP IP Chapter (http://www.keionline.org/node/2239), and earlier we published a Japan proposal for the RCEP IP Chapter (http://keionline.org/node/2173)

Today we are publishing two new proposals for the RCEP IP Chapter, the proposals by

US Copyright office proposes limits on damages, injunctions, for Orphan Works, contradicting TPP language

The US Copyright Office has proposed limitations on damages and injunctions, when "orphan" copyrighted works are infringed.

Leaked IP Chapter, Regional Comprehensive Economic Partnership (RCEP) FTA, Oct 3, 2014

Attached (here) is the October 3, 2014 version of the Draft Text, of the Intellectual Property Chapter, for the Regional Comprehensive Economic Partnership (RCEP), Free Trade Agreement, tabled by South Korea in the negotiations. (More about the RCEP here)

The next round of negotiation will be held in Kyoto, Japan from 8-12 June.

Put the patents at risk, not the patients

The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.

KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and Development

Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34

My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.

I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.

We have suggestions for some changes in the discussion, to move things forward.

USTR's 2015 Special 301 List

Every year USTR issues a list of countries targeted to be subjected to trade pressures over their policies on intellectual property rights. This year's list was published on April 30, 2015. KEI has a copy of every version of the Special 301 list here: http://www.keionline.org/ustr/special301

USTR describes the list as follows:

The Special 301 Process

OCR version of leaked EU document on : "A digital single market strategy for Europe"

Yesterday, Politico published this story:

Leaked digital single market’s ‘evidence file’ reveals Commission’s ambitions. Documents show policy came before evidence for cybersecurity measures.
By ZOYA SHEFTALOVICH 20/4/15, 1:29 PM CET Updated 21/4/15, 11:33 AM CET

The CA State Assembly Health Committee staff analysis of AB463; includes who supports and opposes

The California Assembly Health Committee has published an analysis of AB463, the Pharmaceutical Cost Transparency Act of 2015. The bill will be marked up by the committee on Tuesday (April 21). The analysis was written by Dharia McGrew. It recommends three amendments to the bill, and provides a discussion of the benefits of the required disclosures, with context, and describes the support and opposition. The staff report is attached, and below is a list of 33 groups supporting and 22 opposing the bill.

State of California considers AB463, a bill to require disclosure of drug development costs, and more economic data

This is a bill that will see legislative action next week in California, and the bill has some momentum. This is the first time I have seen any government make an effort to have useful data on the economics drug drug development and pricing, and it provides a model that other governments may want to built upon.

A mark-up on the bill has been scheduled for Tuesday, April 21, 2015, in the Assembly Health Committee.


INTRODUCED BY Assembly Member Chiu

FEBRUARY 23, 2015

Sony complains fundraiser: "smells a little bit like a Disney play regarding corp. tax reform"

This from the Wikileaks Sony Archive:

An email from Keith Weaver, the "Executive Vice President, Worldwide Government Affairs at Sony Pictures Entertainment, provide an illustration the practical art of doing "Government Affairs," meeting "goals" for fundraisers, trying to avoid making "personal" contributions, and wondering if the donations were to much focused on another company's purchase of policy" "smells a little bit like a Disney play regarding corp. tax reform".


From: Weaver, Keith
Sent: Tuesday, August 26, 2014 5:23 PM
To: Weil, Leah

KEI and Public Citizen ask the NIH for safeguards in patent license for HCV drug

The following attached letter [PDF ], from KEI and Public Citizen, asks the NIH to impose certain conditions on an exclusive license on NIH owned patents for a drug to treat the hepatitis C virus (HCV). The NIH wants to license the patents to Virotas Biopharmaceuticals, LLC, a company having a place of business in California. Other than the patents involved, the NIH requires people to sign a non-disclosure to know more about the deal.

Twenty groups write Congress, no fast track without public access to trade agreement negotiating texts

Twenty groups, including KEI, have written Congress, asking the Congress to provide public access to draft trade agreement texts and U.S. proposals throughout negotiations, and to specific that only agreements developed through such processes should obtain any expedited congressional consideration.

Among other things, the groups said:

Syndicate content